



ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20260814043

Date: August 14, 2026

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India SCRIP CODE: 543275	To, National Stock Exchange of India Limited 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India SYMBOL: ANURAS
---	--

Dear Sir/Madam,

Subject: Investor Presentation- Q1 of FY27

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the 'Investor Presentation' in respect of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026, of Anupam Rasayan India Limited (the "Company").

The Investor Presentation will also be hosted on the website of the Company at www.anupamrasayan.com.

We request you to kindly note the same and take into your records.

Thanking you,

Yours Faithfully,

For Anupam Rasayan India Limited

**ASHISH
GUPTA**

Digitally signed by
ASHISH GUPTA
Date: 2026.08.14
12:18:57 +05'30'

Ashish Gupta
Company Secretary & Compliance Officer

Encl.: As above

Registered Office:

Office Nos. 1101 to 1107, 11th Floor, Icon Rio,
Behind Icon Business Centre, Dumas Road,
Surat-395007, Gujarat, India.

Tel. : +91-261-2398991-95
Fax : +91-261-2398996
E-mail : office@anupamrasayan.com
Website : www.anupamrasayan.com
CIN - L24231GJ2003PLC042988



ANUPAM RASAYAN INDIA LTD.

Anupam Rasayan India Limited

Q1 FY27

Investor Presentation



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Anupam Rasayan India Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe to any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over-runs on contracts, our ability to manage our international operations, government policies and actions, regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

01

Quarterly
Highlights



Consolidated
Total Revenue

₹6,675 Mn

Y-o-Y growth of **36%**

Consolidated
EBITDA*

₹1,749 Mn

Y-o-Y growth of **35%**

Consolidated
Profit After Tax

₹512 Mn

Y-o-Y growth of **6%**

Standalone
Total Revenue

₹3,349 Mn

Y-o-Y growth of **4%**

Standalone
EBITDA*

₹1,155 Mn

Y-o-Y growth of **17%**

Standalone
Profit After Tax

₹320 Mn

Y-o-Y growth of **8%**

Added

3 New

Products in Q1FY27
taking total to

**125+
Products**

Financials

- **Consolidated Total Income** for the quarter came in at Rs 6,675 Mn with a strong growth of 36% on a YoY basis driven by new product commercialization and healthy demand across all segments
- **Consolidated EBITDA** for the quarter also grew by 35% on YoY basis and came in at Rs 1,749 Mn with margins at 26% showcasing our continuous focus on high value products.

New Development

- World's first company to **commercialize ETFA (Ethyl Trifluoroacetate)** using flow chemistry.
- Signed an **LoI with BASQUEVOLT, S.A.**, creating a potential revenue opportunity of up to \$300 million over a 10-year period with expected commercialization in FY27
- Well-positioned for the next growth phase, driven by increasing contribution from Performance Materials and Pharmaceuticals, strong customer engagement, and expanding global opportunities.

New Products Commercialized

- **Pharma Segment:** Added 1 new intermediate for new drug to the portfolio, further strengthening our offerings and expanding opportunities in the pharmaceutical segment..
- **Performance Material Segment:** Added 2 new products used as monomer for new reinforced polyester and high-performance engineering fluid, broadening our product portfolio and strengthening our capabilities to cater to evolving customer requirements.

Acquisition

- **Bliss GVS Pharma acquisition** progressing as planned, expected to strengthen Anupam's pharmaceutical platform through regulated manufacturing and enhanced CDMO capabilities.
- Successfully **completed the acquisition of Jayhawk Fine Chemicals**, strengthening its globally integrated specialty chemicals and CDMO platform with enhanced manufacturing footprint, advanced chemistry capabilities, high-value chemistries, and strong proforma annual performance.

Mr. Anand S Desai

MANAGING DIRECTOR

"We are pleased to begin fiscal year 2027 on a strong note. Consolidated Revenue for the quarter grew 36% year-on-year, a result that reflects sustained momentum across our businesses and continued execution of our strategy to build a globally integrated specialty chemicals and CDMO platform.

We would like to highlight an important technological milestone achieved during the quarter. We became the first company in the world to commercialize Ethyl Trifluoroacetate, or ETFA, using flow chemistry — a significant advancement that further strengthens our capabilities in complex fluorination.

We also signed a Letter of Intent with BASQUEVOLT, S.A. for the potential long-term supply of a specialty chemical product. This represents a revenue opportunity of approximately US\$300 million spread over a period of ten years.

Turning to our pharmaceutical business, the proposed acquisition of Bliss GVS Pharma continues to progress as planned, following the signing of the definitive agreement. Upon completion, we expect this transaction to strengthen our pharmaceutical platform through synergies across CDMO capabilities, product development, customer relationships, and access to regulated markets.

Looking ahead, we remain confident in our growth prospects. This confidence is supported by a strong product pipeline, expanding opportunities across our Performance Materials and Pharmaceuticals segments, deeper customer engagement, and continued investment in technology and innovation. Together, these initiatives position us well to deliver sustainable growth and long-term value creation."



Consolidated Quarterly Profit & Loss Statement

Particulars (₹ Mn)	Q1FY27	Q1FY26	YoY	FY26
Revenue from Operations	6,550	4,858		23,655
Other Income	126	49		182
Total Income	6,675	4,907	36%	23,836
Cost of materials consumed	2,847	2,439		13,233
Employee Expenses	649	203		866
Other Expenses	1,430	974		4,308
EBITDA	1,749	1,292	35%	5,430
EBITDA Margin (%)	26%	26%		23%
Depreciation	561	307		1,399
EBIT	1,189	985		4,031
Finance Cost	492	357		1,487
Profit before Tax	697	629		2,544
Tax	185	144		322
Profit After Tax	512	485	6%	2,222
PAT Margin (%)	8%	10%		9%
EPS	3.40	3.10		15.09
Cash Profit	1,073	792		3,953

Standalone Quarterly Profit & Loss Statement


Particulars (₹ Mn)	Q1FY27	Q1FY26	YoY	FY26
Revenue from Operations	3,288	3,157		16,756
Other Income	61	48		200
Total Income	3,349	3,205	4%	16,955
Cost of materials consumed	1,386	1,411		9,401
Employee Expenses	121	123		451
Other Expenses	687	680		2,852
EBITDA	1,155	991	17%	4,252
EBITDA Margin (%)	34%	31%		25%
Depreciation	317	264		1,148
EBIT	838	726		3,104
Finance Cost	421	337		1,394
Profit before Tax	417	389		1,709
Tax	97	92		95
Profit After Tax	320	297	8%	1,614
PAT Margin (%)	10%	9%		10%
EPS	2.81	2.70		14.32
Cash Profit	637	561		2,762

02

Business
Overview



ANUPAM RASAYAN INDIA LIMITED



Leading Custom Synthesis Manufacturer



Consolidated Financials (as on FY26)

Revenue
Rs. 23,836 Mn

EBITDA
Rs. 5,430 Mn (23%)

PAT
Rs. 2,222 Mn (9%)

Fast growing Specialty Chemical Manufacturer with focus on Custom Synthesis.

Longstanding relationships with leading MNCs

Leveraging deep expertise across complex chemistries

Building platforms across business verticals of Agro, Personal Care, Pharma and Performance Materials

On track to achieve **best-in-class ESG standards by 2028**



Energy net zero by 2028 on Scope 1+2 emissions

PHASE I- INCEPTION

1984

Formed partnership firm "Anupam Rasayan"

2006

Started supplying Anti-Bacterial products for German MNC

2010

Started supplying to Syngenta

2014

Commercialized large scale manufacturing site - Unit 4

2016

Awarded 'Green Innovation Award' by Corning Reactor Technology

PHASE II- BUILD UP

2017

Started supplying to Sumitomo Japan

2019

Commercialized 2 more manufacturing sites – Unit 5 & 6

2020

Received DSIR registration for R&D Centre

2021

- Started supplying to Adama
- Listed on NSE and BSE
- Commissioned Solar Power Plant of 12.5MW at Bharuch

PHASE III- THE ACCELERATION

2022

- Acquired controlling stake in **Tanfac Industries Ltd.**

2023

- Raised ₹5,000 mn. through QIP
- Commissioned Solar Power Plant of 5.4MW at Bharuch


2024

- Raised ₹5,500 mn. through Preferential Issue
- Commissioned Hybrid Power Plant of 9.6MW

2026

- Acquired U.S. based **Jayhawk Fine Chemicals Corporation**
- Signed definitive agreement to acquire **Bliss GVS Pharma Limited**

Consolidated Revenue:



01

LIFE SCIENCE RELATED SPECIALITY CHEMICALS

a. Agrochemicals (including Crop Protection)

Manufacturing agrochem intermediates and agrochem active ingredients (insecticides, fungicides and herbicides)

b. Personal Care

Manufacturing anti-bacterial and ultraviolet protection intermediates and ingredient

c. Pharmaceuticals

Developing intermediates and 'key starting materials' for APIs, material sciences and surface chemistry

02

PERFORMANCE MATERIALS

a. Polymer

Manufacturing specialty monomers, ionomers, and oligomers, including high-performance materials for defense, aerospace, and semiconductor applications, utilizing anhydrous hydrogen fluoride across both fluorinated and non-fluorinated chemistries

b. Electronic Chemicals

Manufacturing niche molecules for the electronics ecosystem, offering high-quality, low metal content advanced materials used in display chemicals, heat transfer fluids, and AR/VR applications, along with solutions for frontend and backend semiconductor processes, including organic and inorganic fluoride-based battery chemicals.

03

OTHER FLUORINATED PRODUCTS (TANFAC)

a. Portfolio of fluorine-based chemicals, led by Hydrofluoric Acid and its derivatives, alongside Aluminium Fluoride, Potassium Fluorides, Boron Trifluoride Complexes and specialty fluorinated products.

b. Products serve critical applications across agrochemicals, pharmaceuticals, refrigerants, solar cells, fluoropolymers, lithium batteries, metallurgy and other advanced industrial segments.

Few Top Global Clientele

 SUMITOMO CHEMICAL Nissei Corporation

41%

Of Consolidated Revenue

31%

Of Consolidated Revenue

28%

Of Consolidated Revenue

& 55+

Other MNC's

State of the Art Manufacturing Facilities

**8**
Manufacturing Plants*

**2,500+**
Employees

Equipped with
Pilot Plant Facility

Strategically located
Near **Hazira Port**

Certifications



- ▶ **Glass-lined, Titanium clad stainless-steel reactors** enabling diverse range of products
- ▶ **State-of-the-art infrastructure**, including Continuous flow Silicon Carbide and glass reactors (Corning G1 and G4)
- ▶ **World class quality control** system with continuous improvement

Location	Units	Installed Capacity (In MT)
Anupam Rasayan		
Sachin, Gujarat	Unit 1	5,202
	Unit 2	2,520
	Unit 3	6,190
	Unit 6	2,487
Jhagadia, Gujarat	Unit 4	5,425
	Unit 5	8,028
Tanfac Industries		
Cuddalore, Tamil Nadu	Sulphuric Acid	1,00,000
	Hydrofluoric Acid	29,700
	Specialty Fluorides	5,000
Jayhawk Fine Chemicals		
Kansas, U.S	Unit 1	36,000
Total		2,00,552

*Includes Tanfac and Jayhawk Facilities

Strong Manufacturing Footprint – India and USA



14+
Countries Exports
presence

36%
of Revenue from
International Business
(Q1FY27)

8 Manufacturing Facilities

- 4 Plants in Sachin, Gujarat
- 2 Plants in Jhagadia, Gujarat
- 1 Plant in Cuddalore, Tamil Nadu
- 1 Plant in Kansas, USA


5 Sales Offices

- India
- Japan
- Switzerland
- USA
- UAE

4 R&D Centers

- Sachin, Gujarat
- Jhagadia, Gujarat
- Cuddalore, Tamil Nadu
- Kansas, USA

90+ Molecules Under Development



Deep expertise in complex chemistries

Vapour Phase Chlorination & Fluorination	Ethoxylation	Grignard	Pyridine
Etherification	Chlorination	Bromination	Sandmeyer
Esterification	Diazotization & Hydrolysis	Condensation	Acylation
Amination	Vilsmeier Haack	Aminolysis	Oxidation
Nitration	Pinner Reaction	Hydrogenation	Fluorination

Process Technologies

Flow Chemistry

- ▶ Improved Safety
- ▶ Improved Reaction control & Better Yields
- ▶ Reduced Environmental & Energy Footprint



Photo Chemistry

- ▶ Simplified synthesis of complex molecules
- ▶ Larger potential for automation
- ▶ Increased access to novel compounds




R&D Engine



90+ Experienced R&D scientist including **10% PhDs**



50+ new products launched since FY20



4 modern and dedicated R&D facilities, **2 DSIR-recognized**



Mr. Anand S Desai

MANAGING DIRECTOR

Over 30 years of experience in chemicals industry associated with company since 1992 & was one of first Directors of company



Mrs. Mona A Desai

VICE-CHAIRPERSON & WHOLE-TIME DIRECTOR

Over 20 years of experience in chemicals industry and associated with the Board since the incorporation of the company



Mr. Gopal Agrawal

CHIEF EXECUTIVE OFFICER

Qualified CA with 25+ yrs. Exp in Corporate Strategy, global M&A and Mgmt Consultancy. Former MD & Head - IB at Edelweiss India



Mr. Ravi Desai

CHIEF OPERATING OFFICER

20+ years of experience in sales; with ARIL for ~14 years



Mr. Amit Khurana

CHIEF FINANCIAL OFFICER

Qualified CA with 15+ yrs. exp in taxes/accounts; Former Head of Indirect Taxes & Costing of co., with ARIL for ~10years



Dr. Nileshkumar Naik

TECHNICAL HEAD

PhD (Chem), M.Sc. (Organic chemistry); with ARIL since incorporation



Dr. Anuj Thakar


WHOLE TIME DIRECTOR AND R&D HEAD

PhD (Chem), M.Sc. (Organic chemistry); with ARIL for ~18 yrs.

03

Moving up the
Value Chain








Company acquired management control in May'22 at a market cap of Rs 5,950 Mn

Key Rationale




- **Uninterrupted access** to key raw materials (HF and KF) for fluorination chemistry
- Enable **future expansion** of product series under fluorination chemistry
- **Reduce import dependence**
- **Increased capacities of existing product portfolio** of Tanfac through process improvement & debottlenecking

Company Details

- **50 years old** specialty fluoride chemical manufacturer in India
- **Leading producer** of hydrofluoric acid (HF) and organic and inorganic fluorine-based products
- **Focused R&D** in niche & advanced fluorine derivatives over last 5 years

Revenue Trend (Rs Crores)



Fluorine chemistry has become increasingly integral to new product innovation across agrochemicals, pharmaceuticals, polymers and EV.



Anupam has acquired Jayhawk Fine Chemicals LLC, U.S.-based specialty chemicals company, at an **enterprise value of ~\$134Mn** (total purchase consideration of ~\$150Mn includes ~\$16Mn of cash & cash equivalents on Jayhawk's balance sheet) which will be **funded through combination of internal accruals, debt and quasi equity**

Key Details



Description:

Manufactures performance materials (~65%)
& life / crop science molecules (~35%)

Founded in 1941, located in Kansas, U.S



Financials:

Revenue: ~\$76 Mn

EBITDA: ~\$15 Mn (~19% Margins)



Business Model:

Manufactures high-value specialty intermediates for performance materials and life sciences supported by complex chemistries, specialized manufacturing capabilities and long-standing customer relationships.



Employees:

~140 FTEs with majority of employees in operations




~800 acres in the U.S.

with <10% utilized, offering strong expansion headroom

Jayhawk strengthens Anupam's global manufacturing and technology capabilities while accelerating diversification into high-value, less-cyclical segments such as performance materials

Jayhawk – Expanding Footprint In the USA Market



Participation in high value markets

Expands access to fast-growing, innovation-led segments such as semiconductors, automotive / EV, aviation and electronics



US-based platform for CDMO expansion

Offers a strategically valuable platform for Anupam to expand presence in the US and build a global CDMO network (in line with long-term expansion strategy)



Facilitates Sectoral Diversification

Expands the business beyond agrochemicals and pharmaceuticals into high-value, relatively less-cyclical segments such as performance polymers and polyimides.



Complementary tech & integration advantage

Strong synergies via complementary tech – leveraging Jayhawk's high-purity tech with Anupam's backward integration capabilities to enable dual-site production and faster scale-up



Access to strategic customer base

Strengthening access to leading global customers and opens new downstream opportunities



Critical RM control

Differentiated material platforms

High value end markets



TANFAC

(HF & KF production)

HF

KF



ANUPAM RASAYAN

(Advanced intermediates)

Fluorinated
Intermediates

Aromatic
Diamines

Non- Fluorinated
Intermediates



(Synthesis &
transformation)

Aromatic
Dianhydrides

Custom
Synthesis

Polymers
(Polyimides | Epoxies)

Electronic Chemicals
(Semiconductor materials)

API / advance pharma
intermediates

Crop Protection Actives /
Intermediates

Electric Vehicles

Global footprint and combined capabilities supporting independent specialty manufacturing platform

- Incorporated in 1984.
- Manufactures branded formulations across Anti-malarial, Anti-fungal, Anti-bacterial, Antibiotic, anti-inflammatory, Anti-infective, Anti-diabetic, Cardiovascular, Gastrointestinal, Respiratory, Urology and contraceptive segments.
- Renowned for its flagship anti-malarial WHO endorsed brand (Lonart).
- Long-standing distributor relationships (spanning over 20-25 years).
- Bliss GVS Pharma is the first EU-GMP certified suppositories manufacturer in India.
- 6 Manufacturing facilities in Palghar, Vevoor and Ambarnath across Maharashtra.



150+
Brands



50+
Therapeutic
segments



16+
Dosage forms



1,000+
Employees



80+
Scientists

Global Accreditations



& **25+** Accreditations



Signed Strategic agreements in USA and Canada, along with recent USFDA approval to Palghar suppository unit to bring significant revenue potential.



Synergies with Therapeutic Areas:

Expansion into Cardiovascular, Antidiabetic, Antibiotics, Analgesic & Anti-inflammatory, Anti-Retrovirals, Antifungals, Anti-depressant and Anti-malarial segments



Expansion into CDMO Business:

Expanding into regulated markets through Vevoor facility.



Forward Integration:

End-to-End Vertically integrated Manufacturing to give cost and resource leverage.



Capacity Utilization Ramp Up:

Significant headroom available to improve capacity utilization, supported by customer engagements, and increasing demand across key business segments



Expanding USA Footprint:

Using our expertise in North America to expand in regulated markets

Key Therapeutic Areas

Cardiovascular

Anti-Diabetic

Antibiotics / Anti Bacterial

Analgesic, Anti-Inflammatory

Antiretrovirals

Antifungals

Anti-Depressant

Anti-Malarial

Robust pipeline of 62+ molecules over the next two years, with 48+ molecules catering to regulated markets, strengthening the Company's presence in high-entry-barrier segments



Deal overview



Proposed Stake to be Acquired:


43.3-48.2% + Open Offer acquisition of Bliss GVS Pharma



Purchase Consideration of ~Rs 1,600 Crore

(Non-Controlling Non-voting equity instrument of ~Rs 1,300 Crores & Term Loan of ~Rs 300 Crores)

Transaction structure



04

Growth Drivers





Pharmaceutical & Polymer Expansion

- Increasing contribution from high-growth Polymer & Pharma CDMO business
- Better product mix expected to support margins

Long-Term LOIs & Customer Contracts

- Strong revenue visibility through multi-year LOIs and long-term customer contracts
- Strategic partnerships with global innovators

Strengthening Supply Chain

- Integration in Customer supply Chain
- Acquisition of Tanfac for backward integration
- Forward Integration through Jayhawk acquisition

Sustainable Business Model

- Partner of choice for originators/leading MNC
- Multi pronged strategy leading to high growth

Building a globally diversified specialty chemicals platform through higher-value products, long-term customer relationships and strategic acquisitions.

Strong Order Book: Recent LOI/Contracts Signed

Signing Quarter	Segment	Customer	LOI/Contract	Tenor (Years)	Status	Value (₹ Crores)
Q1FY22	Life Science	Multinational Life Science Company	LOI	5	Commercialized	1,100
Q1FY22	Life Science	Two Multinational Companies	Contract	5	Commercialized	540
Q2FY22	Life Science	European Multinational Company	Contract	5	Commercialized	144
Q3FY22	Life Science	Japanese Multinational Company	Contract	4	Commercialized	135
Q4FY22	Life Science	Multinational Crop Protection Company	LOI	5	Commercialized	700
Q4FY23	Life Science	Japanese Chemical Company	LOI	6	To be commercialized in FY27	984
Q1FY24	Other Specialty Chemical	Japanese Multinational	LOI	7	Commercialized	1,500
Q1FY24	Other Specialty Chemical	American Multinational	LOI	5	To be commercialized in FY27	380
Q1FY24	Life Science	Japanese Chemical Company	LOI	5	To be commercialized in FY28	2,186
Q3FY24	Other Specialty Chemical	Japanese Multinational Chemical Company	LOI	9	Commercialized	507
Q4FY24	Other Specialty Chemical	Japanese Multinational	LOI	7	Commercialized	743
Q4FY25	Other Specialty Chemical	US Multinational Company	LOI	10	Commercialized	1,697
Q4FY25	Other Specialty Chemical	US Multinational Company	Contract	1	Commercialized	108
Q4FY25	Battery Chemical	Elementium	LOI	5	To be commercialized in FY27	3,000
Q4FY25	Other Specialty Chemical	Korean Multinational	LOI	10	To be commercialized in FY27	922
Q1FY27	Other Specialty Chemical	BASEQUEVOLT, S.A	LOI	10	To be commercialized in FY27	2,850
Total						17,496


Pharma

New Strategic Custom Development Products under pipeline to be manufactured by Anupam in India:



- Import Substitute "Key Starting Materials"
- To manufacture KSM/intermediates for blockbuster molecules

Polymer



- Key Monomers for Speciality and high-end Polymers which are currently being manufactured in Japan and US.
- CDMO projects for manufacturing Polymers for Originators.

65+

Number of molecules of pharma and polymer in R&D and pilot

10+

Number of molecules in pharma and polymer commercialized in last 2 years



Company Details:



ANUPAM RASAYAN INDIA LTD.

Anupam Rasayan India Limited

CIN – L24231GJ2003PLC042988

www.anupamrasayan.com

Investor Relations Advisor :

SGA Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Mr. Shrikant Sangani / Ms. Shaily Patwa

Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net

Mobile No – 9619595686 / 9819494608

www.sgapl.net

Thank You